Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS.

Blut. 1985 Jan;50(1):1-6. Unique Identifier : AIDSLINE MED/85098213
Kern P; Toy J; Dietrich M

Abstract: The toxicity of recombinant Interleukin-2 (IL-2) was studied in patients with acquired immunodeficiency syndrome (AIDS) or persistent lymphadenopathy syndrome (LAS). Increasing doses of the drug from 10(3) Units/m2 to 10(6) U/m2 were given as an intravenous bolus injection. At the high-dose levels some minor effects, such as fever up to 39.5 degrees C, chills, malaise or vomiting, were observed. The administration of 10(6) U/m2 as a 4-hour infusion showed identical results. No particular alterations of laboratory parameters were found. At the high-dose level the serum concentration of neopterin, which is released from macrophages after interferon gamma stimulation, was significantly (p less than 0.001) elevated above pretreatment levels. The clinical observation of daily infusions of 10(6)/m2 for 14 days revealed the same side effects. All patients developed lymphocytosis and eosinophilia. Two patients had suffered from severe diarrhoea for several weeks presumably due to cryptosporidiosis. In both cases diarrhoea ceased under the treatment with IL-2 and did not occur in the following two months.
Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Adult Animal Biopterin/ANALOGS & DERIVATIVES/BLOOD Cryptosporidiosis/COMPLICATIONS Diarrhea/DRUG THERAPY/ETIOLOGY Fever/CHEMICALLY INDUCED Human Interleukin-2/ADVERSE EFFECTS/*THERAPEUTIC USE Lymphatic Diseases/*DRUG THERAPY Male Sarcoma, Kaposi's/DRUG THERAPY Skin Manifestations Syndrome T-Lymphocytes/CLASSIFICATION JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDdrugtherapyadultanimalbiopterin/analogs&derivatives/bloodcryptosporidiosis/complicationsdiarrhea/drugtherapy/etiologyfever/chemicallyinducedhumaninterleukin-2/adverseeffects/KWDtherapeuticuselymphaticdiseases/KWDdrugtherapymalesarcoma,kaposi's/drugtherapyskinmanifestationssyndromet-lymphocytes/classificationjournalarticle
850530
M8550059

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .